Last reviewed · How we verify
GSI-953
At a glance
| Generic name | GSI-953 |
|---|---|
| Also known as | Begacestat, WAY-210953, PF-05212362 |
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953 (PHASE1)
- Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population (PHASE1)
- Study Evaluating The Coadministration of Begacestat And Donepezil (PHASE1)
- Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSI-953 CI brief — competitive landscape report
- GSI-953 updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI